Analysts have clear opinions on RIGL.
There are 3 analysts on the Wall offering 12 month price targets for Rigel in the last 3 months. The average price target is $7.00 with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 222.58% increase from the last price of $2.17.
Rigel Pharmaceuticals, Inc. (RIGL) is followed by 3 analysts on the street.
null from rates it a .
Similarly, null of a with a target of .
The consensus on the street is Strong Buy.
What does Rigel Pharmaceuticals, Inc.(RIGL) do ?
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Rigel Pharmaceuticals, Inc. (RIGL) Insider Trades
Multiple company employees have indulged in significant insider trading. Rigel Pharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
EVP,CFO, Schorno Dean L : P – Purchase(+$106,544) of RIGL in the trading session of 2019-05-22.
Principal Accounting Officer Cabatuan Nelson : S – Sale(-$31,200) of RIGL in the trading session of 2018-10-12.
EVP, Chief Medical Officer Duliege Anne-Marie : S – Sale+OE(-$535,500) of Rigel Pharmaceuticals, Inc. in the trading session of 2018-09-17.
Looking for stocks just like RIGL?
Based on Wall Street analyst research, several stocks are similar to RIGL
– BMY [Info can be found here: https://www.nasdaq.com/market-activity/stocks/BMY ]
– ACRS [Info can be found here: https://www.nasdaq.com/market-activity/stocks/ACRS ]
– AZN [Info can be found here: https://www.nasdaq.com/market-activity/stocks/AZN ]